This website uses cookies. By continuing to access the site you are agreeing to their use. Learn more about cookies.

Select country
  • language Clinigen Australia
  • language Clinigen France
  • language Clinigen Germany
  • About Clinigen
    • About us
    • History
    • Board of Directors
    • Responsible business
    • Operational excellence
    • Our brands
  • Global offices
    • Australia & New Zealand
    • Mainland Europe
    • Japan
    • Singapore
    • South Africa
    • United Kingdom
    • United States
  • Careers
    • Careers overview
    • Apply Online
    • Frequently Asked Questions
    • Privacy Notice - Applicants
  • Investors
    • At a Glance
    • Financial Highlights
    • Investment Case
      • Business Model
      • Our Track Record
      • Market Overview
      • Strategy
      • Our Businesses
    • Share Tools
    • Results, Reports and Presentations
    • Quantum Archive
    • Financial Calendar
      • Events
    • Press Releases
      • Press Releases
      • Regulatory News
      • Email Alerts
    • Shareholder Services
      • AGM
      • Registrar Services
      • Major Shareholders
      • Advisor Contacts
      • Analyst Coverage
    • AIM Rule 26
    • Corporate Governance
      • Corporate Governance Statement
      • Board of Directors
      • Tax Strategy
    • Investor Contacts
  • Newsroom
    • Video Library
    • Press Releases
    • Stay In Touch
Clinigen-Logo.png
  • Mission
  • How we can help
    Pharmaceutical & Biotech Companies
    Healthcare Professionals
    Patient Groups
    Patients
  • Medicines & Services
    Commercial Medicines >
    • CARDIOXANE®
    • ETHYOL®
    • FOSCAVIR®
    • GLYCOPYRRONIUM BROMIDE 1MG/5ML ORAL SOLUTION
    • IMUKIN® / IMMUKIN® / IMMUKINE®
    • MELATONIN 1MG/ML ORAL SOLUTION
    • MELATONIN 3MG FILM-COATED TABLETS
    • PROLEUKIN®
    • SAVENE® (Non US)
    • TOTECT® (US only)
    • Partnering with Clinigen
    Unlicensed Medicines >
    • Policy Development
    • Asset Strategy
    • Early Access
    • Real World Evidence
    • Post-Trial Access
    • Phased Launch and Non-Launch Markets
    • Medicine Shortages
    • Market Withdrawal/ Discontinuations
    • Consulting Services
    Clinical Trial Services >
    • Comparator Sourcing
    • Packaging, Labelling and Distribution
    • Investigator Initiated Trials (IITs)

    Find a medicine

    Online services for healthcare professionals

    Hard to find medicines (Clinigen Direct) Managed Access Programs (Cliniport) Commercial Medicines Special Obtains Aseptics UK
  • Insights
Find a medicine
Hard to find medicines (Clinigen Direct)
Managed Access Programs (Cliniport)
Clinigen Products
  • CARDIOXANE®
  • ETHYOL®
  • FOSCAVIR®
  • GLYCOPYRRONIUM BROMIDE 1MG/5ML ORAL SOLUTION
  • IMUKIN®
  • MELATONIN 1MG/ML ORAL SOLUTION
  • MELATONIN 3MG FILM-COATED TABLETS
  • PROLEUKIN®
  • SAVENE® (Non US)
  • TOTECT® (US only)
  • Partnering with Clinigen
Special Obtains
Aseptics UK
Get in touch
Get in touch
Find a medicine
Hard to find medicines (Clinigen Direct)
Managed Access Programs (Cliniport)
Clinigen Products
  • CARDIOXANE®
  • ETHYOL®
  • FOSCAVIR®
  • GLYCOPYRRONIUM BROMIDE 1MG/5ML ORAL SOLUTION
  • IMUKIN®
  • MELATONIN 1MG/ML ORAL SOLUTION
  • MELATONIN 3MG FILM-COATED TABLETS
  • PROLEUKIN®
  • SAVENE® (Non US)
  • TOTECT® (US only)
  • Partnering with Clinigen
Special Obtains
Aseptics UK
  • Mission
  • How we can help
    How we can help
    • Pharmaceutical & Biotech Companies
    • Healthcare Professionals
    • Patient Groups
    • Patients
  • Medicines & Services
    Medicines & Services
    • Commercial Medicines >
      Commercial Medicines >

      Commercial Medicines >

      • CARDIOXANE®
      • ETHYOL®
      • FOSCAVIR®
      • GLYCOPYRRONIUM BROMIDE 1MG/5ML ORAL SOLUTION
      • IMUKIN® / IMMUKIN® / IMMUKINE®
      • MELATONIN 1MG/ML ORAL SOLUTION
      • MELATONIN 3MG FILM-COATED TABLETS
      • PROLEUKIN®
      • SAVENE® (Non US)
      • TOTECT® (US only)
      • Partnering with Clinigen
    • Unlicensed Medicines >
      Unlicensed Medicines >

      Unlicensed Medicines >

      • Policy Development
      • Asset Strategy
      • Early Access
      • Real World Evidence
      • Post-Trial Access
      • Phased Launch and Non-Launch Markets
      • Medicine Shortages
      • Market Withdrawal/ Discontinuations
      • Consulting Services
    • Clinical Trial Services >
      Clinical Trial Services >

      Clinical Trial Services >

      • Comparator Sourcing
      • Packaging, Labelling and Distribution
      • Investigator Initiated Trials (IITs)

    Find a medicine

    Online services for healthcare professionals

    Hard to find medicines (Clinigen Direct) Managed Access Programs (Cliniport) Commercial Medicines Special Obtains Aseptics UK
  • Insights
  • About Clinigen
    About Clinigen

    About Clinigen

    • About us
    • History
    • Board of Directors
    • Responsible business
    • Operational excellence
    • Our brands
  • Global offices
    Global offices

    Global offices

    • Australia & New Zealand
    • Mainland Europe
    • Japan
    • Singapore
    • South Africa
    • United Kingdom
    • United States
  • Careers
    Careers

    Careers

    • Careers overview
    • Apply Online
    • Frequently Asked Questions
    • Privacy Notice - Applicants
  • Investors
    Investors

    Investors

    • At a Glance
    • Financial Highlights
    • Investment Case
      Investment Case

      Investment Case

      • Business Model
      • Our Track Record
      • Market Overview
      • Strategy
      • Our Businesses
    • Share Tools
    • Results, Reports and Presentations
    • Quantum Archive
    • Financial Calendar
      Financial Calendar

      Financial Calendar

      • Events
    • Press Releases
      Press Releases

      Press Releases

      • Press Releases
      • Regulatory News
      • Email Alerts
    • Shareholder Services
      Shareholder Services

      Shareholder Services

      • AGM
      • Registrar Services
      • Major Shareholders
      • Advisor Contacts
      • Analyst Coverage
    • AIM Rule 26
    • Corporate Governance
      Corporate Governance

      Corporate Governance

      • Corporate Governance Statement
      • Board of Directors
      • Tax Strategy
    • Investor Contacts
  • Newsroom
    Newsroom

    Newsroom

    • Video Library
    • Press Releases
    • Stay In Touch
Events Calendar

EVENTS

  • At a Glance
  • Financial Highlights
  • Investment Case
    • Business Model
    • Our Track Record
    • Market Overview
    • Strategy
    • Our Businesses
  • Share Tools
  • Results, Reports and Presentations
  • Quantum Archive
  • Financial Calendar
    • Events
  • Press Releases
    • Press Releases
    • Regulatory News
    • Email Alerts
  • Shareholder Services
    • AGM
    • Registrar Services
    • Major Shareholders
    • Advisor Contacts
    • Analyst Coverage
  • AIM Rule 26
  • Corporate Governance
    • Corporate Governance Statement
    • Board of Directors
    • Tax Strategy
  • Investor Contacts
Date Event
24 March 2020 Berenberg UK Corporate Conference
18 May 2020 Berenberg US Conference
19 May 2020 RBC Global Healthcare Conference

Share Tools

Share Tools

View all
Services

Early Access

Annual Report

Annual Report 2019

Download report (pdf 2.84mb)
Our global offices
  • Australia & New Zealand
  • Mainland Europe
  • Japan
  • Singapore
  • South Africa
  • United Kingdom
  • United States
Site
tools
  • Stay In Touch
  • AE Reporting
  • Medical enquiries
  • Terms of use
  • Cookies
  • Privacy policy
  • UK Gender Pay Gap Report
  • Modern Slavery Statement
  • Access Online
  • Sitemap
  • Consumer Information Obligations
Find a medicine

Online services for healthcare professionals

Hard to find medicines (Clinigen Direct) Managed Access Programs (Cliniport) Clinigen Products Special Obtains Aseptics UK
  • Twitter
  • Vimeo
  • Linkedin
© Copyright 2019 Clinigen Group plc. By Emperor